drugset / Trial / NCT00548340

VEC-162 Study in Adult Patients With Primary Insomnia

NCT00548340

Phase 3 Completed 322 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.

Timeline

Start
2007-11
Primary completion
2008-02
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject tasimelteon Small molecule 20 mg Oral
Subject tasimelteon Small molecule 50 mg Oral

Indications